Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | PLAU | P00749 | 3/20 | 0.36 |
| ▸ | PLAT | P00750 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.30 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713842 | 0.81 | NOS3 (0.50) | NOS3NOS1NOS2 | |
| SCHEMBL28452456 | 0.81 | PLAU (0.35) | IDO1PLAUPLATBACE1 | |
| SCHEMBL2034977 | 0.81 | CSF1R (0.40) | CSF1RIDO1PLAUPLATNOS3 | |
| SCHEMBL10017416 | 0.81 | MAP4K4 (0.49) | CSF1R | |
| SCHEMBL1748589 | 0.79 | NOS3 (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL2637090 | 0.79 | KMT2A (0.47) | CSF1RIDO1PLAUNOS3NOS1 | |
| SCHEMBL15900365 | 0.76 | KDM4E (0.34) | PLAUPLAT | |
| SCHEMBL17883465 | 0.75 | IDO1 (0.35) | IDO1PLAUPLATBACE1 | |
| SCHEMBL25220652 | 0.75 | PLAU (0.31) | PLAUPLAT | |
| SCHEMBL1714544 | 0.75 | ALDH1A1 (0.39) | CSF1RPLAUNOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111416154-B | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2021-08-06 | — | — | CN | claimed |
| CN-111416154-A | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2020-07-14 | — | — | CN | claimed |
| CN-118955507-A | Preparation method of 5-halogenated azaindole | 深圳格林凯特医药技术有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-111416154-B | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2021-08-06 | — | — | CN | disclosed |
| CN-110128421-B | Simple preparation method of 5-halogenated-7-azaindole | 新发药业有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-RE48140-E1 | Furanone derivative | CARNA BIOSCIENCES, INC. (JP) | 2020-08-04 | — | — | US | disclosed |
| CN-111416154-A | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2020-07-14 | — | — | CN | disclosed |
| EP-2692728-B1 | NOVEL FURANONE DERIVATIVE | CARNA BIOSCIENCES INC (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-RE46815-E1 | Furanone derivative | CARNA BIOSCIENCES, INC. (JP) | 2018-05-01 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| WO-2008004117-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | VERTEX PHARMACEUTICALS INCORPORATED | 2007-02-22 | — | — | US | disclosed |
| EP-1732546-A2 | NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | Aventis Pharma S.A. (FR) | 2006-12-20 | — | — | EP | disclosed |
| EP-1730146-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005095400-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-10-13 | — | — | WO | disclosed |
| WO-2005095399-A2 | NOVEL PYRROLO (2,3-B)PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152103-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | JAK3, JAK2, JAK1 | CSF1R 1917/4885IDO1 630/4885PLAU 3033/4885 |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | CSF1R 2615/4885IDO1 223/4885PLAU 3218/4885 |
| US-20070043063-A1 | Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders | LCK, PDXK, CHUK | CSF1R 940/4885IDO1 270/4885PLAU 2380/4885 |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | MAP3K19, MAP4K2, MAP3K1 | CSF1R 1304/4885IDO1 3101/4885PLAU 2257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.